Payment overview · 2025
General Payments
$179.87
9 reported records · 6 companies
Healthcare provider profile · identity verified
Daniel Alan Pedersen, DO
Allopathic & Osteopathic Physicians|Family Medicine|Adult Medicine · WEEKI WACHEE, FL · NPI 1619327780
Verified facts
What the public records show
CMS Open Payments records show Daniel Alan Pedersen, DO received $179.87 in general payments during 2025 across 9 reported records.
AstraZeneca Pharmaceuticals LP accounted for 44.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $80.78 | 44.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27.19 | 15.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.17 | 13.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.07 | 11.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.12 | 7.8% | 1 | 2025 |
| Fidia Pharma USA Inc. | Unresolved — no canonical attribution shown | $13.54 | 7.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $179.87 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $42.87 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $37.91 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $27.19 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| HYMOVIS Normalized: hymovis |
Device | Fidia Pharma USA Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| TRILURON Normalized: triluron |
Device | Fidia Pharma USA Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 378 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 304 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 302 | 88 |
| Losartan Potassium | Losartan Potassium | 237 | 62 |
| Alprazolam | Alprazolam | 230 | 51 |
| Lisinopril | Lisinopril | 214 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 213 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 182 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 177 | 49 |
| Omeprazole | Omeprazole | 173 | 50 |
| Gabapentin | Gabapentin | 155 | 49 |
| Metformin Hcl | Metformin Hcl | 151 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 36 |
| Trazodone Hcl | Trazodone Hcl | 136 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 118 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 33 |
| Meloxicam | Meloxicam | 108 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 31 |
| Tramadol Hcl | Tramadol Hcl | 102 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 35 |
| Furosemide | Furosemide | 94 | 35 |
| Montelukast Sodium | Montelukast Sodium | 92 | 27 |
| Prednisone | Prednisone | 91 | 50 |
| Simvastatin | Simvastatin | 90 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 27 |
| Temazepam | Temazepam | 82 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 79 | 22 |
| Buspirone Hcl | Buspirone Hcl | 76 | 20 |
| Potassium Chloride | Potassium Chloride | 72 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 25 |
| Metformin Hcl Er | Metformin Hcl | 64 | 19 |
| Glipizide | Glipizide | 63 | 16 |
| Famotidine | Famotidine | 59 | 18 |
| Spironolactone | Spironolactone | 58 | 14 |
| Eliquis | Apixaban | 57 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 55 | 21 |
| Allopurinol | Allopurinol | 54 | 17 |
| Ezetimibe | Ezetimibe | 54 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 11 |
| Chlorthalidone | Chlorthalidone | 52 | 12 |
| Finasteride | Finasteride | 52 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 16 |
| Clonazepam | Clonazepam | 51 | 13 |
| Lorazepam | Lorazepam | 50 | 14 |
| Pregabalin | Pregabalin | 49 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 11 |
| Carvedilol | Carvedilol | 48 | 14 |
| Diazepam | Diazepam | 46 | 14 |
| Azithromycin | Azithromycin | 45 | 41 |
| Glimepiride | Glimepiride | 45 | 13 |
| Methocarbamol | Methocarbamol | 43 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 42 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 39 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | 11 |
| Jardiance | Empagliflozin | 35 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 31 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 12 |
| Clonidine Hcl | Clonidine Hcl | 30 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | 11 |
| Atenolol | Atenolol | 27 | suppressed |
| Carbamazepine | Carbamazepine | 26 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | suppressed |
| Nystatin | Nystatin | 25 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 21 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 14 |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 13 |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 11 |
| Naproxen | Naproxen | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 14 | 14 |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $179.87 · 9 records | AstraZeneca Pharmaceuticals LP | BREZTRI, CAPVAXIVE, Cologuard Collection Kit, FARXIGA, HYMOVIS, MOUNJARO, TRILURON, VRAYLAR, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error